期刊文献+

153例三阴性乳腺癌的临床病理特征分析 被引量:6

下载PDF
导出
摘要 目的探讨三阴性乳腺癌的临床病理特征和预后。方法回顾性分析627例乳腺癌患者的临床资料,其中雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER-2)表达均为阴性者153例,为三阴组,其余为非三阴组。结果三阴组年龄≤50岁者90例(58.82%),非三阴组162例(34.17%),两组年龄相比P<0.01。三阴组未绝经者87例(56.86%),非三阴组187例(39.45%),两组绝经情况相比P<0.01。三阴组腋窝淋巴结转移66例(43.13%),非三阴组167例(35.23%),两组腋窝淋巴结转移率相比P<0.05。三阴组临床分期Ⅰ~Ⅱ、Ⅲ级者分别为112、41例,非三阴组分别为282、192例,两组临床分期Ⅲ期比例相比P<0.05。三阴组发生复发、转移者45例(29.41%),其中肺、肝、骨、脑转移分别为18、5、12、3例,局部胸壁复发7例,无对侧乳腺转移病例,随访期内死亡28例(18.30%),除3例死于肺转移并发脑栓塞外,其余均死于远处脏器转移。非三阴组发生复发转移187例(18.35%),其中肺、肝、骨、脑转移分别为14、9、35、5例,局部胸壁复发17例,对侧乳腺转移7例,随访期内死亡53例(11.18%),两组复发转移率、死亡率相比P均<0.05。三阴组的5年无病生存率为70.6%,生存率为81.7%,非三阴组分别为81.65%、88.81%两组相比P均<0.05。结论三阴性乳腺癌发病年龄较轻,未绝经者较多,淋巴结转移率较高,组织学分级较高,术后复发转移率高,5年无病生存率和总生存率较低。
出处 《山东医药》 CAS 2012年第6期61-62,共2页 Shandong Medical Journal
  • 相关文献

参考文献9

  • 1Perou CM,Sorlie T,Eisen Mb,et al.Molecularportraits of humanbreast tumors[J].Nature,2000,406(6797):747-752.
  • 2Cheang MC,Voduc D,Bajdik C,et al.Basal like breast cancer de-fined by five bio markers has superior prognostic value than triplenegative phenotype[J].Clin Cancer Res,2008,14(5):1368-1376.
  • 3Gerson R,Alban F,Villalobos A,et al.Recurrence and survivalrates among early breast cancer cases with triple negative immuno-phenotype[J].Gac Med Mex,2008,144(1):27-34.
  • 4Mise M,Higashide S,Hashimoto K,et al.Clinicopathological fea-tures of young patients with triple negative breast cancer[J].GanTo Kagaku Ryoho,2009,36(10):1677-1681.
  • 5Mersin H,Yildirim E,Berberoglu U,et al.The prognostic impor-tance of triple negative breast carcinoma[J].Breast,2008,17(4):341-346.
  • 6Rhee J,Han SW,Oh DY,et al.The clinicopathologic characteris-tics and prognostic significance of triple-negativity in node-negativebreast cancer[J].BMC Cancer,2008,8(3):307.
  • 7Dent R,Trudeau M,Pritchard KI,et al.Triple-negative breastcancer:clinical features and patterns of recurrence[J].Clin CancerRes,2007,13(15):4429-4434.
  • 8Young SR,Pilarski RT,Donenberg T,et al.The prevalence of BRCA1 mutations among young women with triple negative breastcancer[J].BMC Cancer,2009,9(4):86.
  • 9Daniel PS,Andrea L,Richardson AC,et al.Efficacy of neoadju-vant cisplatin in triple-negative breast cancer[J].Clin Oncol,2010,28(7):1145-1153.

同被引文献73

  • 1陈燕昌,林舜国,郑宇辉,梁建纲,许春森,韩晖,陈大良.乳腺癌Ki-67抗原和DNA倍体的相关性及临床意义[J].福建医科大学学报,2005,39(1):48-50. 被引量:15
  • 2张斌.老年人乳腺癌[J].中国癌症杂志,2005,15(5):422-425. 被引量:39
  • 3李亚芬.老年人乳腺癌的处理原则[J].外科理论与实践,2006,11(2):100-101. 被引量:13
  • 4赵卫红,徐兵河,李青,张频,孙燕.70岁以上老年女性乳腺癌患者的特点和预后分析[J].中华肿瘤杂志,2006,28(5):385-388. 被引量:69
  • 5Sasa M, Bando Y, Takahashi M, et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer[J]. J Surg Oncol, 2008, 97(1): 30-4.
  • 6Reis-Filho JS, Tutt AN. Triple negative tumours:a critical re- view[J]. Histopathology, 2008, 52(1 ) : 108-18.
  • 7Dent R, Hanna WM, Trudeau M, et al. Pattern of metastatic spread in triple-negative breast cancer[J]. Breast Cancer Res Treat,2009,115(2) : 423-8.
  • 8Hurvitz SA, Allen HJ, Moroose RL, etal. A phase II trial of docetaxel with bevaeizumab as first-fine therapy for HER2 negative metastatic breast eancer(TORI B01)[J]. Clin Breast Cancer, 2010, 10(4): 307-12.
  • 9Gerdes J, Schwab U, Lemke H, et al. Production of a mouse mo- noclonal antibody reactive with a human nuclear antigen associ- ated with cell proliferation[J]. Int J Cancer, 1983,31 ( 1 ) : 13-20.
  • 10MacCallum DE, Hall PA. The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle[J]. J Pathol,2000,190 (5) :537-544.

引证文献6

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部